Abstract
BackgroundThe anti-NKG2A monoclonal antibody (mAb), NNC141-0100, may potentially reduce inflammation in Rheumatoid Arthritis (RA) and other immune disorders via a novel mechanism of action. NNC141-0100 has been proposed to promote...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
